The value of sPESI for risk stratification in patients with pulmonary embolism.


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
Jul 2019
Historique:
pubmed: 8 2 2019
medline: 18 12 2019
entrez: 8 2 2019
Statut: ppublish

Résumé

Various risk stratification methods exist for patients with pulmonary embolism (PE). We used the simplified Pulmonary Embolism Severity Index (sPESI) as a risk-stratification method to understand the Veterans Health Administration (VHA) PE population. Adult patients with ≥ 1 inpatient PE diagnosis (index date = discharge date) from October 2011-June 2015 as well as continuous enrollment for ≥ 12 months pre- and 3 months post-index date were included. We defined a sPESI score of 0 as low-risk (LRPE) and all others as high-risk (HRPE). Hospital-acquired complications (HACs) during the index hospitalization, 90-day follow-up PE-related outcomes, and health care utilization and costs were compared between HRPE and LRPE patients. Of 6746 PE patients, 95.4% were men, 67.7% were white, and 22.0% were African American; LRPE occurred in 28.4% and HRPE in 71.6%. Relative to HRPE patients, LRPE patients had lower Charlson Comorbidity Index scores (1.0 vs. 3.4, p < 0.0001) and other baseline comorbidities, fewer HACs (11.4% vs. 20.0%, p < 0.0001), less bacterial pneumonia (10.6% vs. 22.3%, p < 0.0001), and shorter average inpatient lengths of stay (8.8 vs. 11.2 days, p < 0.0001) during the index hospitalization. During follow-up, LRPE patients had fewer PE-related outcomes of recurrent venous thromboembolism (4.4% vs. 6.0%, p = 0.0077), major bleeding (1.2% vs. 1.9%, p = 0.0382), and death (3.7% vs. 16.2%, p < 0.0001). LRPE patients had fewer inpatient but higher outpatient visits per patient, and lower total health care costs ($12,021 vs. $16,911, p < 0.0001) than HRPE patients. Using the sPESI score identifies a PE cohort with a lower clinical and economic burden.

Identifiants

pubmed: 30729377
doi: 10.1007/s11239-019-01814-z
pii: 10.1007/s11239-019-01814-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-157

Références

Cerebrovasc Dis. 2009;28(4):378-83
pubmed: 19641313
Swiss Med Wkly. 2009 Nov 28;139(47-48):685-90
pubmed: 20047130
Adv Ther. 2010 Sep;27(9):648-54
pubmed: 20694805
Arch Intern Med. 2010 Aug 9;170(15):1383-9
pubmed: 20696966
Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):560-6
pubmed: 21387461
Arch Intern Med. 2011 May 9;171(9):831-7
pubmed: 21555660
Stroke. 2011 Nov;42(11):3214-8
pubmed: 21868737
Exp Clin Cardiol. 2013 Spring;18(2):129-38
pubmed: 23940438
Thromb Res. 2013 Nov;132(5):515-9
pubmed: 24035045
J Thromb Haemost. 2013 Dec;11(12):2103-10
pubmed: 24119089
Thromb Res. 2014 Jun;133(6):1006-10
pubmed: 24690480
South Med J. 2014 Feb;107(2):72-8
pubmed: 24926670
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k
pubmed: 25173341
Clin Ther. 2015 Jan 1;37(1):62-70
pubmed: 25524389
Thromb Res. 2015 Feb;135(2):303-10
pubmed: 25555319
Acad Emerg Med. 2015 Mar;22(3):299-307
pubmed: 25716463
Int J Cardiol. 2015 Oct 15;197:162-3
pubmed: 26142198
J Thromb Thrombolysis. 2016 May;41(4):606-12
pubmed: 26255069
Thrombosis. 2015;2015:175357
pubmed: 26294971
BMJ Open. 2015 Oct 28;5(10):e009251
pubmed: 26510731
Intern Emerg Med. 2016 Feb;11(1):11-8
pubmed: 26768476
J Thromb Thrombolysis. 2016 Jan;41(1):3-14
pubmed: 26780736
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Crit Care Nurs Q. 2016 Apr-Jun;39(2):131-8
pubmed: 26919674
BMJ Open. 2016 Apr 29;6(4):e010324
pubmed: 27130162
Intern Emerg Med. 2017 Apr;12(3):311-318
pubmed: 27757790
Eur Heart J. 2019 Mar 14;40(11):902-910
pubmed: 30590531

Auteurs

Phil Wells (P)

University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada.

W Frank Peacock (WF)

Baylor College of Medicine, Houston, TX, USA.

Gregory J Fermann (GJ)

University of Cincinnati, Cincinnati, OH, USA.

Craig I Coleman (CI)

University of Connecticut, Storrs, CT, USA.

Li Wang (L)

STATinMED Research, Analytic Research, Plano, TX, USA. lwang@statinmed.com.

Onur Baser (O)

Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
STATinMED Research, Health Economics & Outcomes Research, New York, NY, USA.

Jeff Schein (J)

Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

Concetta Crivera (C)

Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH